Navigation Links
The hepatitis healing power of blueberry leaves
Date:8/7/2009

A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, opening up a new avenue for treating chronic HCV infections, which affect 200 million people worldwide and can eventually lead to cirrhosis and liver cancer.

Among the areas of especially high Hepatitis C incidence is the Miyazaki prefecture of southern Japan, a trend that led Hiroaki Kataoka and colleagues at the University of Miyazaki and elsewhere in Japan on a search for better treatment options. Currently, there is no vaccine for HCV, and though a combination drug regimen can clear HCV infection, this treatment is only about 60% effective on average and poses risks of severe side effects.

Kataoka and colleagues believed that since HCV is localized in the liver and can take 20 years or more to develop into disease, a dietary supplement might help slow or stop disease progression. So they screened nearly 300 different agricultural products for potential compounds that suppress HCV replication and uncovered a strong candidate in the leaves of rabbit-eye blueberry (native to the southeastern US).

They purified the compound and identified it as proanthocyandin (a polyphenol similar to the beneficial chemicals found in grapes and wine). While proanthocyandin can be harmful, Kataoka and colleagues noted its effective concentration against HCV was 100 times less than the toxic threshold, and similar chemicals are found in many edible plants, suggesting it should be safe as a dietary supplement. In the meantime, the researchers now hope to explore the detailed mechanisms of how this chemical stops HCV replication.


'/>"/>

Contact: Nick Zagorski
nzagorski@asbmb.org
301-634-7366
American Society for Biochemistry and Molecular Biology
Source:Eurekalert

Page: 1

Related biology news :

1. First human gets new antibody aimed at hepatitis C virus
2. Novel antibody prevents infection by hepatitis C virus
3. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
4. When acute hepatitis develops into chronic hepatitis
5. Discovery could lead to a new animal model for hepatitis C
6. Leeds research points to new therapy for hepatitis C treatment
7. Nano vaccine for hepatitis B shows promise for third world
8. Hepatitis C virus may need enzymes help to cause liver disease
9. BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients
10. New hope for hepatitis C sufferers
11. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology: